MediChip™ Platform
Solid Tumors (e.g., Colorectal Cancer)
Pre-clinicalActive
Key Facts
About BioSapien
BioSapien is a private, pre-revenue biotech developing the MediChip™, a 3D-printed, biodegradable implant for localized, sustained drug delivery to solid tumors. The platform aims to mitigate the severe side effects of systemic chemotherapy by targeting the tumor directly, potentially improving outcomes and enabling more patients to undergo curative surgery. The company has secured $3M in total funding, including seed investment from SOSV and Hikma Ventures, and has achieved key regulatory clarity with the FDA's confirmation of a 505(b)(2) approval pathway for its lead program.
View full company profile